NASDAQ: ATHE - Alterity Therapeutics Limited

Rentabilität für sechs Monate: +175%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan Alterity Therapeutics Limited

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen Alterity Therapeutics Limited

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease.

weitere details
It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2002-09-05
ISIN US02155X1063
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета aud
Сайт https://alteritytherapeutics.com
Цена ао 3.56
Preisänderung pro Tag: 0% (3.3)
Preisänderung pro Woche: +19.78% (2.755)
Preisänderung pro Monat: -18.11% (4.03)
Preisänderung über 3 Monate: -0.3924% (3.313)
Preisänderung über sechs Monate: +175% (1.2)
Preisänderung pro Jahr: +54.21% (2.14)
Preisänderung über 3 Jahre: +306% (0.8128)
Preisänderung über 5 Jahre: +436.67% (0.6149)
Preisänderung seit Jahresbeginn: +57.14% (2.1)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 2454.6 1
P/BV 715.01 1
P/E 0 0
EV/EBITDA -503.45 0
Gesamt: 0.625

Effizienz

Name Bedeutung Grad
ROA, % -82.18 0
ROE, % -104.47 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0081 10
Gesamt: 9.8

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 876.58 10
Rentabilität Ebitda, % 89.99 9
Rentabilität EPS, % -48.11 0
Gesamt: 6.6
Weitere Details

Institutionen Volumen Aktie, %
Morgan Stanley 51485 0.7
Bank of Montreal/Can/ 14907 0.2
Twin Lakes Capital Management, LLC 5925 0.08
Providence Capital Advisors, LLC 200 0
Coppell Advisory Solutions, LLC 149 0
Osaic Holdings Inc 81 0
Sugarloaf Wealth Management, LLC 33 0
Steward Partners Investment Advisory, LLC 6 0



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Geoffrey Paul Kempler B.Sc. Co-Founder & Non-Executive Chairman 207.52k 1955 (70 Jahre)
Dr. David A. Stamler M.D. Chief Executive Officer 613.33k 1961 (64 Jahr)
Dr. Rudolph Emile Tanzi Ph.D. Chief Scientific Advisor and Member of Research & Development Advisory Board N/A 1959 (66 Jahre)
Dr. Robert Cherny Head of Research N/A
Mr. Phillip Allen Hains BBus(Acc), C.A., M.B.A. CFO & Company Secretary N/A 1959 (66 Jahre)
Dr. Steven D. Targum M.D. Chief Medical Advisor

Adresse: Australia, Melbourne, 350 Collins Street - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://alteritytherapeutics.com